Company Snapshot

Investment Thesis

Eli Lilly is a global biopharma leader with best-in-class assets in obesity, diabetes, immunology, and neuroscience. Blockbuster incretin therapies Mounjaro and Zepbound drive outsized growth while a deep pipeline supports durable cash flows.

  • Incretin Leadership: Tirzepatide and retatrutide offer multi-year runway in obesity and metabolic disease.
  • Pipeline Depth: Alzheimer’s candidate donanemab and oncology assets like Jaypirca expand future franchises.
  • Manufacturing Scale: Massive capex in U.S. and Europe facilities mitigates supply constraints and defends market share.

Revenue Mix

Diabetes & Obesity 45% — Mounjaro, Trulicity, Zepbound
Immunology 20% — Taltz, Olumiant
Oncology 15% — Verzenio, Jaypirca
Neuroscience & Other 20% — including donanemab launch

Mix reflects Eli Lilly 2024 sales commentary.

Recent Performance

MTD +5.03%
QTD +9.80%
YTD +16.48%
5Y +509.93%

Performance is powered by explosive demand for obesity treatments, successive label expansions, and high-margin biologics. Valuation remains rich, making execution on supply build-out and pipeline milestones critical.

Strategic Insights

Metabolic Expansion

Next-gen small molecules and oral GLP-1s aim to broaden obesity care beyond injectables.

Neuro Innovation

Donanemab and lecanemab-to-come create a foothold in Alzheimer’s with potential health-system redesigns.

Digital Companions

Connected devices and patient support programs reinforce adherence and expand real-world data.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...